Combination Chemotherapy of Oxaliplatin and Capecitabine in Patients with Metastatic Colorectal Cancer: a Pilot Study

Myung‐Ju Ahn(Sungkyunkwan University), Heung Woo Lee(Hanyang University), Ho Suck Oh(Hanyang University Seoul Hospital), Oh Young Lee(Hanyang University), Il Young Choi(Hanyang University), Jung Hye Choi(Hanyang University Guri Hospital), Young Yeul Lee(Hanyang University), In Soon Kim(Hanyang University Seoul Hospital)
Cancer Research and Treatment
October 31, 2003
10.4143/crt.2003.35.5.407
Cited by 2

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537